Fmr LLC Buys 286,052 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Fmr LLC boosted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 10.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,908,918 shares of the company’s stock after acquiring an additional 286,052 shares during the quarter. Fmr LLC owned 0.09% of Takeda Pharmaceutical worth $41,365,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its position in shares of Takeda Pharmaceutical by 38.6% during the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after buying an additional 859 shares during the period. Smithfield Trust Co boosted its position in Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after acquiring an additional 1,490 shares during the last quarter. Hexagon Capital Partners LLC grew its stake in shares of Takeda Pharmaceutical by 34.3% during the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock worth $63,000 after acquiring an additional 1,129 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Takeda Pharmaceutical during the 2nd quarter worth approximately $59,000. Finally, Blue Trust Inc. raised its holdings in shares of Takeda Pharmaceutical by 74.0% in the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock valued at $76,000 after purchasing an additional 2,330 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $13.73 on Friday. The stock has a market capitalization of $43.69 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 0.25 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The firm has a fifty day simple moving average of $13.88 and a 200 day simple moving average of $13.86. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.